Xilio
Xilio Therapeutics Stock Plunges Following Initial Phase 2 Data for Vilastobart in Colorectal Cancer Treatment
Xilio Therapeutics, Vilastobart, Anti-CTLA-4, Colorectal Cancer, Stock Price, Phase 2 Data
Gilead Partners with Xilio Therapeutics for Novel Tumor-Activated IL-12 Program
interleukin-12, Xilio, XTX301, development aspects